HonorHealth is a community hospital group, not an academic medical center, but it has nevertheless committed significant resources to its research programs.
Some of its early work over the past several years has centered on finding targeted therapeutics for cancer, and it has had good success. But the five-hospital system is increasingly interested in finding biomarkers that can help predict who might be at risk for illness.
HonorHealth is one of a number of health systems that are investing in genomics and personalized medicine as the next frontier in healthcare. As providers are tasked with keeping people healthy through risk-based payment contracts, they’re searching for new ways to target patients who need early intervention. Venture capital funds also have been flowing into the space, as investors expect rapid growth.